Cash and Investments: As of September 30, 2010, Lexicon had $231.0 million in cash and investments, as compared to cash and investments, net of its obligations under the credit line secured by its auction rate securities, of $255.8 million as of June 30, 2010 and $125.1 million as of December 31, 2009. On June 30, 2010, Lexicon exercised its rights to require UBS AG to purchase its remaining auction rate securities, and UBS purchased the auction rate securities at par value on July 1, 2010.
Lexicon Conference Call:Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the third quarter of 2010 at 11:00 a.m. Eastern Time on November 5, 2010. The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 20791091. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through November 12, 2010.
About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery ef
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved